Navigation Links
Zysolin(TM) Pre-clinical Data Supports Once-a-day Dosing in Humans
Date:6/18/2009

    AlphaRx's inhaled Tobramycin nanoparticle formulation provides 300% more
    availability than standard free drug in lung tissue, as demonstrated in a
    recent animal pharmacokinetic study.

MARKHAM, ON, June 18 /PRNewswire-FirstCall/ - AlphaRx (OTC BB:ALRX) is pleased to report a significant breakthrough in the development of Zysolin(TM), an inhaled Tobramycin nanoparticle formulation utilizing the company's proprietary drug delivery platform, and intended for the adjunctive treatment of Pseudomonas Aeruginosa Pneumonia in intubated and mechanically-ventilated patients (VAP).

In a recent pivotal animal PK (pharmacokinetic) study, Zysolin(TM) delivered 300% more drug to lung tissue than free drug, when utilizing the same delivery method. This data demonstrates that Zysolin(TM) provides superior lung tissue penetration and a release profile which supports once-a-day human dosing frequency.

The study data will be presented, by invitation, to the upcoming July meeting of the Controlled Release Society Conference in Copenhagen, Denmark.

Dr. Michael Weisspapir, MD, PhD, Chief Medical Scientist of AlphaRx commented, "As a result of this pre-clinical data, we anticipate that the demonstrated superiority over free drug availability will result in higher drug concentrations in lung tissue, enhancing clinical efficacy for VAP patients in vivo."

About Zysolin(TM)

Zysolin(TM) is a Tobramycin compound, encapsulated in AlphaRx's Nano Drug Delivery Platform, intended for the adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients. Zysolin(TM) improves the intracellular activity of Tobramycin - in layman's term, increasing the drug concentration of Tobramycin inside human macrophages, thus improving its antibacterial activity against intracellular Klebsiella, Pseudomondas aeruginosa and Staphylococcus bacterial strains in pneumonia patients. The active ingredient in Zysolin(TM), Tobramycin, has a long-standing and proven clinical treatment record. Delivered by inhalation, using proprietary nanotechnology developed by AlphaRx, the company believes Zysolin(TM) will have an attractive safety, tolerability and efficacy profile when compared to injectible Tobramycin.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the companies.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PointCross Releases Pre-Clinical Study Lifecycle and Data Management Suite (PC-LDM(TM)) For Multi-Party Environments
2. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
3. Akela Pharma receives letter from the FDA regarding its pre-clinical toxicology studies for Fentanyl TAIFUN(R)
4. Bioniche Presents Pre-Clinical Research at Two International Conferences
5. Senesco Announces Results of Pre-Clinical Efficacy, Toxicology and Dose Ranging Studies for Multiple Myeloma Therapeutic Candidate
6. Drug inhibits neuroblastoma blood supply in pre-clinical tests
7. Drug therapy reduces neuroblastoma tumor growth in pre-clinical investigation
8. HealthFitness CEO Supports Move Toward Cultural Shift, and Science-Based Health Management Programming
9. Diageo Supports First Ever National We Dont Serve Teens Week
10. The Prem Rawat Foundation Supports Disaster-Relief Efforts in Mozambique
11. Discovery supports theory of Alzheimers disease as form of diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... PA (PRWEB) , ... December 09, 2016 , ... "I ... Fla. "I used this old family recipe, which is meant to relieve gout and ... it gave me a 12-hour energy boost every time. It relieved what VA doctors ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy ... in New York, NY, on December 3rd, to benefit Holy Name Medical Center's ... annual event, which raised over $1 million - the largest event in the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Fla. , Dec. 9, 2016  Harmar Mobility, LLC announced ... and a member of the Board of Directors. Photo ... ... Mr. Dawson,s ... development of organizations across a variety of industries. He brings to ...
(Date:12/9/2016)... -- Research and Markets has announced the addition of ... offering. ... global travel vaccines market to grow at a CAGR of 6.83% ... scenario and the growth prospects of the global travel vaccines market ... revenue generated from the sales of various vaccines administered to actively ...
(Date:12/8/2016)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... stock, $0.01 par value (the "Offering" with such shares being ... terms of the Offering will depend on market and other ... no assurance as to whether or when the Offering may ... proceeds it will receive from this offering for working capital ...
Breaking Medicine Technology: